Introduction
HIV-associated neurocognitive impairment (NCI) is highly prevalent in the modern era of combination antiretroviral therapy (ART) [1] , and older adults appear to be particularly vulnerable to HIV-associated NCI [2] [3] [4] [5] . Persons living with HIV (HIV-positive) who are untreated for cerebrovascular risk demonstrate poorer performance in the neurocognitive domains of processing speed, learning/memory and executive functioning than HIV-positive persons who are pharmacologically treated for cerebrovascular risk [6] .
HIV-positive persons may experience imbalance in coagulation given impaired endothelial function and immune activation [7] [8] [9] . In a subset of participants in the Strategies for Management of Antiretroviral Therapy (SMART) trial, HIV replication was associated with complex changes in the extrinsic pathway, such as shortterm increases in some procoagulants and decreases in anticoagulants [e.g. lower antithrombin (AT) and lower protein C] [10] . Some studies have found that biomarkers indicative of coagulation decrease with initiation of ART [11] ; however, relative to HIV-uninfected (HIV-negative) persons, ART-treated persons appear to be vulnerable to coagulation imbalance [12] . Although untreated patients may have elevated levels of d-dimer (i.e. a fibrin degradation product frequently used as a marker of coagulation disturbances) relative to treated patients on ART, both untreated and treated patients on ART are observed to have impairments in platelet aggregation and clot initiation [13] . Furthermore, older HIV-positive persons may be particularly vulnerable to coagulation imbalance, given that ageing further exerts a strong influence on haemostatic biomarkers, such as d-dimer [14] .
The clinical consequences of HIV disease on coagulation in the context of suppressive ART remain unclear. We aimed to assess the impact of disturbances in coagulation (i.e. coagulation imbalance) on neurocognitive functioning in HIV. We hypothesized that greater coagulation imbalance would have a detrimental effect on neurocognitive functioning in HIV.
Materials and methods

Participants and procedure
The present study examined 100 community-dwelling older (i.e. aged 50 years and above) HIV-positive (n ¼ 66) and HIV-negative adults (n ¼ 34) who participated in the California HIV/AIDS Research Program Successfully Aging Seniors with HIV study at the UCSD HIV Neurobehavioral Research Program. Specific inclusion criteria for HIV-positive participants were being on ART and having an undetectable plasma HIV viral load (<48 copies/ml). General exclusion criteria included use of an anticoagulant medication, history of non-HIV related neurologic disorders or other known conditions that may be associated with impaired neurocognitive performance (e.g. seizure disorder). The study protocol was approved by the UCSD Institutional Review Board. After providing written, informed consent, each participant underwent a standardized neuropsychological, neuromedical and psychiatric evaluation.
Global neurocognitive functioning
Participants completed a standardized neurocognitive test battery (administration time: 2-2.5 h) that assesses seven neurocognitive domains commonly affected by HIV, including speed of information processing, learning, memory, executive functions, verbal fluency, working memory and fine motor function [1] . Raw scores from the neurocognitive tasks were converted to demographically adjusted T-scores (M ¼ 50, SD ¼ 10 in neurological normal individuals) using the best available normative standards [15] [16] [17] . The demographically adjusted T-scores were then averaged to derive neurocognitive domain T-scores and a global T-score, the latter of which was used in statistical analyses as the primary dependent variable. Global T-scores were chosen over other approaches (e.g. deficit scores) given their normal distribution that matches the assumptions of parametric statistical analyses and their wider use across the neuropsychological literature [18] . Higher global Tscores represent better neurocognitive functioning with scores between 35 and 40 reflecting mild impairment.
Plasma biomarkers of coagulation
Biomarker assays were measured by immunoassay in duplicate in EDTA-treated plasma derived from peripheral blood samples collected by routine phlebotomy. Commercial immunoassay suppliers were Millipore (fibrinogen, tissue factor, thrombomodulin; Darmstadt, Germany), R&D Systems [AT, plasminogen activatorinhibitor-1 (PAI-1), protein C, p-selectin, von Willebrand factor (vWF); Minneapolis, Minnesota, USA], SEKISUI (d-dimer; Lexington, Massachusetts, USA) and Cell Biolabs (plasminogen; San Diego, California, USA). Measurements were repeated if the coefficient of variation was greater than 20% or if the measurement was greater than four standard deviations from the mean.
Coagulation imbalance
Coagulation imbalance was operationalized in a similar fashion to other composite indices representing physiological systems [19] . The selected biomarkers represent three physiological systems: procoagulation (fibrinogen, p-selectin, tissue factor, vWF), anticoagulation (AT, protein C, thrombomodulin) and fibrinolysis (d-dimer, PAI-1, and plasminogen). Coagulation imbalance was constructed first by dichotomizing the 10 individual biomarkers on the basis of median splits of the entire sample (i.e. assigning a score of '1' to values in the upper 50th percentile and a score of '0' to values in the lower 50th percentile). The individual binary variables were summed to create summary scores for each of the three physiological systems: procoagulation (values ranging from 0 to 4), anticoagulation (values ranging from 0 to 3) and fibrinolysis (values ranging from 0 to 3). A coagulation imbalance score (values ranging from 0 to 10) was calculated on the basis of summation of the 10 individual biomarker binary variables, with a higher coagulation imbalance score representing more activation/turnover of haemostatic factors.
Plasma biomarkers of inflammation
Biomarkers representing inflammatory processes [i.e. soluble CD163 (sCD163), soluble CD14 (sCD14) and complement C3] [20] were available for a subset of participants (n ¼ 93). Biomarker assays were measured by immunoassay in duplicate in EDTA-treated plasma. The commercial immunoassay suppliers were R&D Systems (sCD163 and sCD14; Minneapolis, Minnesota, USA) and Assaypro (complement C3; St Charles, Missouri, USA). As with the biomarkers of coagulation, measurements were repeated if the coefficient of variation was greater than 20% or the measurement was greater than four standard deviations from the mean.
Covariates
Neuromedical assessment Medical characterization of study participants included medical comorbidities (e.g. dyslipidemia, diabetes mellitus and hypertension) and current prescription medications [i.e. lipid-lowering drug, nonsteroidal anti-inflammatory drug (NSAID), antihypertensive and antidepressant drugs]. Medical comorbidities were defined by the presence of self-reported diagnosis and/or specific drug treatment for the condition (e.g. metformin for diabetes mellitus).
HIV disease characteristics
All HIV-positive participants were on suppressive ART. The following information was obtained for our HIVpositive sample: estimated duration of HIV infection, AIDS diagnosis, current and nadir CD4 þ T-cell counts, and whether or not the participant was on a protease inhibitor based regimen.
Psychiatric assessment
All study participants administered the Composite International Diagnostic Interview [21] to assess for the presence of lifetime and current affective and substance use disorders using diagnostic criteria on the basis of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders [22] . The Beck Depression Inventory-II (BDI-II) [23] was administered to assess current depressive symptoms.
Statistical analyses
The distributions of residuals were visually inspected when performing statistical tests to determine whether transforming individual variables was appropriate to meet statistical assumptions of parametric tests. When appropriate, variables were log 10 transformed. Comparison of demographic, neuromedical and psychiatric data between the HIV-positive and HIV-negative groups was performed with two-tailed t-test or Pearson's chi-squared test, as appropriate. Two-tailed t-tests were conducted to compare individual biomarkers and coagulation composite scores by HIV serostatus. When the assumption of equal variances was not met, Welch's t-test was used. Hedge's g statistic for continuous variables and odds ratios for binary variables were used to generate effect sizes for group comparisons. Next, correlates of coagulation imbalance were explored to identify both personal and inflammatory factors related to coagulation.
To test whether coagulation and HIV have an interacting effect on neurocognitive functioning, four multivariable linear regression models were conducted. Each multivariable model included an HIV by coagulation (i.e. coagulation imbalance, procoagulation, anticoagulation or fibrinolysis) interaction term. Models were run with and without statistical adjustment for relevant covariates. Covariates were selected on the basis of which variables in Table 1 demonstrated univariable associations (i.e. Pearson's correlations for continuous variables and t-tests for categorical variables) with the primary dependent variable (neurocognitive functioning, i.e. global T-score) at a critical a ¼ 0.10. The following covariates were identified as having met our criterion for inclusion in the multivariable analyses: BMI, diabetes mellitus, use of an antidepressant, current major depressive disorder (MDD), lifetime MDD and self-reported depression scores. For analyses only involving the HIV-positive participants, the following HIV disease-specific variables met our criterion for inclusion in the multivariable analyses: current CD4 þ and AIDS status. The variable inflation factor was used to identify multicollinearity among predictor variables prior to final model selection. Final models included only one of the correlated variables. All statistical tests were performed with JMP 11.0.0 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Participants
The sample consisted of 100 participants who were predominantly middle-aged [mean 57.8 (SD 6.0) years], non-Hispanic white (73.0%) men (78.0%) with some college education [mean 14.3 (SD 2.7) years]. Demographic, medical and psychiatric characteristics of the sample are presented in Table 1 .
In general, HIV-positive and HIV-negative groups were largely comparable (i.e. P values for group differences >0.05) across many of the characteristics, including age, education, medical comorbidities (i.e. hypertension, tobacco smoking, diabetes mellitus and hepatitis C), medical prescriptions (i.e. NSAID, antihypertensive and lipid-lowering drug use) and proportion of current MDD and lifetime substance use disorders. The HIV-positive group had more men (84.8% vs. 64.7%, P ¼ 0.02), cases of hyperlipidemia (52.4% vs. 29.4%, P ¼ 0.03), cases of lifetime MDD (57.6% vs. 29.4%, P < 0.01) and a higher proportion on an antidepressant medication (42.4% vs. 11.8%, P < 0.01). The HIV-positive group also had higher scores on a self-report measure of depression symptoms (9.5 vs. 1.5, P < 0.01).
Among the HIV-positive participants (n ¼ 66), the mean estimated duration of HIV infection was 19.4 years, the median current CD4 þ T-cell count was 654 cells/ml and the median nadir CD4 þ T-cell count was 180 cells/ml.
Comparison of coagulation biomarkers between HIV serostatus groups
Of the 10 individual coagulation biomarkers, the HIV serostatus groups only differed on fibrinogen, which was higher in the HIV-negative group (P ¼ 0.04, hedges g ¼ À0.45; Table 2 ). No significant differences were found between the HIV-negative and HIV-positive groups for the coagulation imbalance composite score or the three individual coagulation indices (i.e. procoagulation, anticoagulation and fibrinolysis; P > 0.05). The procoagulant, anticoagulant and fibrinolytic factor indices were not univariably associated with each other (P > 0.05; Table 3 ).
Personal factors and inflammatory biomarkers are associated with coagulation Higher coagulation imbalance scores were univariably associated with higher BMI (r ¼ 0.23, P ¼ 0.02), being on lipid-lowering drug, having a dyslipidemia diagnosis and having a current MDD diagnosis (P < 0.05). Higher coagulation imbalance scores were univariably associated with higher levels of inflammatory biomarkers complement C3 (r ¼ 0.25, P ¼ 0.01), sCD163 (r ¼ 0.24, P ¼ 0.02) and sCD14 (r ¼ 0.22, P ¼ 0.03). Higher procoagulant scores were univariably associated with higher BDI-II scores and both current and lifetime MDD diagnoses (P < 0.05). Higher anticoagulant score was only univariably associated with being on a lipid-lowering drug (P ¼ 0.01), whereas higher fibrinolytic score was univariably associated with higher BMI (r ¼ 0.21, P ¼ 0.03) and complement C3 (r ¼ 0.25, P ¼ 0.02). None of the HIV disease characteristics were univariably associated with any of the coagulation indices within the HIV-positive group (P > 0.05). Fig. 1 ) identified a statistically significant interaction between coagulation imbalance composite score and HIV (b ¼ À0.39, P ¼ 0.01). Follow-up analyses indicated that coagulation imbalance composite score had a statistically significant positive association with neurocognitive functioning among the HIV-positive group (r ¼ À0.30, P ¼ 0.01) but not the HIV-negative group (r ¼ 0.22,
AIDS
The second model of neurocognitive functioning (Model adjusted R 2 ¼ .10, P ¼.005) identified a statistically significant interaction between the procoagulant index score and HIV (b ¼ À0.38, P ¼ 0.02). Similar to the coagulation imbalance composite score, the procoagulant index score had a statistically significant positive association with neurocognitive functioning among the HIV-positive group (r ¼ À0.31, P ¼ 0.01) but not the HIV-negative group (r ¼ 0.18, P ¼ 0.30). Models 1 and 2 and their respective interaction terms remained statistically significant (P < 0.05) after adjusting for relevant covariates (i.e. BMI, diabetes, antidepressant use and current MDD diagnosis). In posthoc analyses, variables associated with coagulation imbalance (i.e. BMI, lipid-lowering drug use, dyslipidemia diagnosis, current MDD diagnosis and inflammatory biomarkers C3, sCD163 and sCD14) were added to Models 1 and 2 to examine whether inflammation, rather than coagulation imbalance, was uniquely associated with neurocognitive functioning. Both models 1 and 2 and their respective interaction terms remained statistically significant (P < 0.05). The inflammatory biomarkers were not statistically significant predictors of neurocognitive functioning in the multivariable models (P > 0.05).
Models 3 and 4 separately tested the interaction between the anticoagulant index score and HIV and the interaction between the fibrinolytic factor score and HIV. Neither model 3 nor 4 was statistically significant with or without adjustment of relevant covariates (overall model P > 0.05).
Procoagulant biomarkers, and not HIV-disease characteristics, are uniquely associated with neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy A series of multivariable models were run that included only the HIV-positive cases in order to adjust for HIVdisease related variables associated with neurocognitive functioning (i.e. AIDS status and current CD4 þ cell count). The procoagulant index remained a statistically significant predictor of neurocognition (b ¼ À0.27, P ¼ 0.03) in a multivariable model adjusting for the effects of BMI, diabetes antidepressant use, current MDD diagnosis, AIDS status and current CD4 þ cell count. None of the covariates included in this multivariable model were statistically significant (P > 0.05). The coagulation imbalance composite score (b ¼ À0.19, P ¼ 0.18) did not remain statistically significant in the multivariable model adjusting for these same covariates. In addition, neither the anticoagulant (b ¼ À0.04, P ¼ 0.76) or fibrinolytic factor (b ¼ 0.01, P ¼ 0.93) indices achieved statistical significance in analogous multivariable models involving only the HIV-positive sample.
Discussion
In our cross-sectional study, levels of soluble biomarkers of procoagulation, anticoagulation and fibrinolysis were comparable between ART-treated virally suppressed HIV-positive older adults and the HIV-negative comparison group. Elevated markers of coagulation were associated with traditional cardiovascular risk factors (e.g. higher BMI and diagnosis and treatment of dyslipidemia) and depressed mood. HIVand coagulation imbalance had an interacting effect on neurocognitive functioning, such that greater coagulation imbalance was associated with poorer neurocognitive functioning among the HIVpositive, but not the HIV-negative, group. The moderating effect of coagulation imbalance appeared to be driven by procoagulant factors, rather than anticoagulant or fibrinolytic markers. These findings indicate that elevated levels of procoagulant markers may exert a particularly detrimental effect on neurocognitive functioning among ART-treated, virally suppressed, HIV-positive older adults.
HIV was not found to confer risk for coagulation imbalance in our study sample consisting of ART-treated, virally suppressed, HIV-positive older adults and an HIVnegative comparison group. Although ART-naive HIVpositive persons show elevated levels of various coagulation-related biomarkers (e.g. fibrinogen, d-dimer and vWF) [24, 25] , it remains unclear whether initiation and long-term use of ART produces a normal coagulation profile. With the initiation of ART, biomarkers of coagulation may decrease (e.g. fibrinogen, d-dimer, vWF and P-selectin) or increase (e.g. protein C and AT), such that levels may be comparable to those among HIVnegative comparison groups [24] [25] [26] [27] . Not all biomarkers, however, may travel with ART status, as was the case of fibrinogen in the SMART study [10] . When comparing HIV-positive adults on vs. off ART, ART does appear to alter coagulation biomarkers, resulting in lower levels of d-dimer [28] [29] [30] [31] , vWF [10, 28, 30, 32] , fibrinogen [33] and PAI-1 [31] , and higher levels of AT [10] and protein C [10, 30] . Comparison between ART-treated HIVpositive persons and HIV-negative comparison groups has yielded mixed results, with some studies reporting differences in levels of coagulation biomarkers (e.g. elevations of d-dimer, thrombomodulin, AT, fibrinogen and PAI-1 among HIV-positive adults) [34] [35] [36] [37] [38] and others finding no differences among the same biomarkers (e.g. comparable levels of thrombomodulin and d-dimer between HIV serostatus groups) [39, 40] .
The profile of coagulation in HIV disease is clearly complex. Discrepant findings in the existing literature are likely an artefact of unique features of individual study cohorts. For example, studies differ on whether participants are in the early and acute infection period vs. long-term survivors of HIV disease. Our study, in particular, enrolled a HIV-positive cohort which was on suppressive ART, and our HIV-negative cohort was recruited to be medically and behaviourally similar to our HIV-positive cohort (e.g. similar prevalence of substance use disorders, diabetes mellitus, hepatitis C). Thus, the results of this study should be interpreted with consideration of our cohort's unique demographic and clinical characteristics.
Specific HIV disease characteristics, such as current CD4 þ T cell count, do not appear to be associated with coagulation indices among older HIV-positive persons. In older HIV-positive persons with virologic suppression on ART, the effect of HIV disease parameters on coagulation may be eclipsed by other factors exerting an influence on hemostasis factors, such as BMI, presence and treatment of dyslipidemia and inflammatory biomarkers. Our failure to detect an association between the coagulation indices and HIV disease characteristics may reflect that this association is weak or absent in the context of ART, viral suppression, chronic HIV disease, older age and/or presence of medical comorbidity burden.
In our study, coagulation biomarkers were related to several inflammatory biomarkers. Specifically, higher coagulation imbalance scores had positive associations with sCD163, sCD14 and complement C3. Monocyte/ macrophage activation is hypothesized to be a source of inflammatory cells in the central nervous system (CNS) and a key mechanism for CNS pathogenesis [41] . Persistent monocyte/macrophage activation, measured by plasma sCD163, has been previously observed in neurophysiologically impaired, HIV-positive individuals on virally suppressive ART [42] . Among chronically infected HIV-positive adults, sCD163 levels appear to decrease with decreasing HIV RNA levels but may not return to seronegative levels, indicating residual monocyte/macrophage activation [43] . Similarly, sCD14, a marker of systemic immune activation, appears to interact with a marker of abdominal obesity on NCI [44] . Complement C3, a primary mechanism of innate immunity, may also be a marker of cardiometabolic risk among persons ageing with HIV [20] . Likely, the relationship between coagulation imbalance and inflammation is bidirectional, with coagulation imbalance being both a consequence of inflammation and an amplifier of the inflammatory response [8] .
Chronic inflammation can lead to disruption of the endothelium, which has been reported in HIV disease [45] [46] [47] . Endothelial dysfunction may play a pivotal role in the pathogenesis of cerebral small vessel disease [48] via the breakdown of the blood-brain barrier [49] and impairment of cerebral reactivity and autoregulation [50] . Haemostatic changes are hypothesized to play a secondary role to endothelial activation, such that damaged endothelial cells can act as a substrate for the initiation of coagulation [51] . The procoagulant index employed in this study was based on values of fibrinogen, p-selectin, tissue factor and vWF. Thus, the procoagulant index may represent both endothelial dysfunction and coagulation imbalance. When accompanied by endothelial dysfunction, elevation in plasma fibrinogen levels has been found to increase the risk of subclinical white matter lesions [52] . Elevation in procoagulant factors, such as fibrinogen, is hypothesized to influence cerebral hypoperfusion and the development of white matter lesions, thereby contributing to neurocognitive decline [52] .
Several limitations of this study should be noted. This study used a cross-sectional, observational design and thus causality from the observed associations among HIV, coagulation imbalance and neurocognitive functioning cannot be inferred. Furthermore, both HIV infection and ART likely exert an influence on neurocognitive functioning, and without an ART-naive comparison sample, we cannot disentangle the effect of ART on neurocognitive functioning. Given that the parent study aimed to investigate 'successful aging' with HIV, there is a high likelihood of selection bias such that we recruited a sample of HIV-positive patients demonstrating good immunologic and virologic profiles, and these older HIVinfected individuals mostly represent a long-term 'survivor' cohort. Lastly, we operationalized the coagulation biomarkers into three theorized physiological systems that have not been previously validated; however, a large panel of biomarkers as utilized in the present study has not been previously used in relation to both HIV and neurocognition. These three physiological systems are likely dynamic and complex, and future research is needed to determine the most optimal method for modelling biomarkers of coagulation.
Endothelial activation and coagulation imbalance likely play mechanistic roles leading to poorer neurocognitive functioning outcomes in HIV-positive adults. Thus, biomarkers of endothelial activation and coagulation may provide valuable information regarding the prognosis and/or risk stratification of HIV-positive adults. Although greater procoagulant values were found to have an association with neurocognitive functioning for ART-treated, virally suppressed, HIV-positive older adults, the clinical utility of coagulation imbalance as a predictor of neurocognitive functioning depends on whether treatment-induced reductions in procoagulant levels translate to improved neurocognitive outcomes. A better understanding of the specific role of coagulation in the cause of HIV-associated neurocognitive disorders may lead to specific treatments aimed at reducing coagulopathy, thereby improving neurocognitive outcomes. 
